Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $6.2 million.

  • Akebia Therapeutics' Treasury Shares rose 5059.62% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 5059.62%. This contributed to the annual value of $4.1 million for FY2024, which is 2300.98% up from last year.
  • Per Akebia Therapeutics' latest filing, its Treasury Shares stood at $162000.0 for Q1 2016.
  • Over the past 5 years, Akebia Therapeutics' Treasury Shares peaked at $7.9 million during Q2 2023, and registered a low of $3.3 million during Q4 2023.
  • For the 5-year period, Akebia Therapeutics' Treasury Shares averaged around $5.1 million, with its median value being $4.4 million (2021).
  • Per our database at Business Quant, Akebia Therapeutics' Treasury Shares crashed by 4518.82% in 2024 and then skyrocketed by 6786.31% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Treasury Shares stood at $4.6 million in 2021, then grew by 24.59% to $5.7 million in 2022, then tumbled by 41.14% to $3.3 million in 2023, then rose by 23.01% to $4.1 million in 2024, then soared by 51.83% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $6.4 million for Q2 2025, and $6.7 million during Q1 2025.